Four traders turned $131,000 into approximately $6 million through TROLL

Avanos Medical Inc announces the expansion of its transformation plan, expecting these initiatives to deliver incremental annualized savings of $15 million to $20 million by the end of 2026.

Biopharmaceutical company Fulcrum Therapeutics recently disclosed that by the end of 2025, its total holdings of cash, cash equivalents, and marketable securities will reach $352.3 million.

First Watch Restaurant Group recently announced its capital expenditure plan for fiscal year 2026, with a total investment expected to reach $150 millions to $160 millions.

Iovance Biotherapeutics recently announced plans to launch a single-arm registration clinical trial in the second quarter of 2026.